Autopsy report · NCT03817190

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Based on Interim Analysis results”

The sponsor’s own words in the registry.

Life of this trial

Registered 8 months before it started.
Ran for about 11 months before it stopped.
219 participants enrolled.
Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: DS Biopharma
Sponsor type: Industry
Conditions: Atopic Dermatitis
Interventions: DS107; Placebo
Participants: 219
Sites: 50
Countries: Austria, Germany, Latvia, Poland, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.